Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine is under clinical development by Chengdu Institute of Biological Products and currently in Phase III for Human Papillomavirus Infections. According to GlobalData, Phase III drugs for Human Papillomavirus Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine overview

The vaccine candidate is under investigation for the prevention of human papilloma virus infections. It is administered through intramuscular route. The drug candidate is a recombinant tetravalent vaccine comprising four serotypes (6,11,16,18) of HPV.

Chengdu Institute of Biological Products overview

Chengdu Institute of Biological Products (CDIBP) focuses on research of medical microbiology, cytology and immunology, producing biological products. CDIBP is headquartered in Chengdu, Chongqing, China.

For a complete picture of Human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.